New Model Validates Hollywood’s Newest Revenue Stream via Blockchain Distribution BEVERLY HILLS, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) — In a groundbreaking venture, global NFT distribution and viewing platform VUELE™ grossed nearly six figures bringing in 32.86267 ETH ($93,435) with
bant.io has become the first B2B lead generation organization to deal in cryptocurrency. bant.io dashboard LONDON, Sept. 29, 2021 (GLOBE NEWSWIRE) — bant.io, the all-in-one B2B lead generation and sales acceleration service, is pushing at the boundaries of conventional business
Report Validates Security Protocols of Delphix’s Masking, Compliance, and SaaS Capabilities REDWOOD CITY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) — Delphix, the industry leading data company for DevOps, today announced that it has successfully completed a Type 1 System and
TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) — Reported diluted earnings per share of $0.21 Mutual fund gross sales of $790 million for the third quarter of 2021, an improvement of 61% year-over-year Mutual fund net sales of $288 million for
Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma – Health Canada Issues Conditional Approval of TRUSELTIQ under Project Orbis (September 27th, 2021) LUGANO, Switzerland, and PALO ALTO, CA,
WM’s ICLM and TUV Unitary Global Payments Systems provide a fully operational and benign model for a functioning Cashless Society worldwide NEW YORK and ST PETER PORT, Guernsey, Sept. 29, 2021 (GLOBE NEWSWIRE) — To create its Global Clearing System
ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study Data from Quantitative Systems Pharmacology/Whole-Body Physiologically Based Pharmacokinetic Modeling Support Evaluation of 300
Philogen Provides Corporate Update Nidlegy™ and Fibromun on track with planned timelines in pivotal clinical trials Use of Nidlegy™ in non-melanoma skin cancer expanded in Phase II clinical trials Early evidence of potent activity of Fibromun in combination with Standard